253 related articles for article (PubMed ID: 27695947)
1. L1CAM: amending the "low-risk" category in endometrial carcinoma.
Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
[TBL] [Abstract][Full Text] [Related]
2. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
3. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
[TBL] [Abstract][Full Text] [Related]
4. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
[TBL] [Abstract][Full Text] [Related]
5. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
Smogeli E; Davidson B; Cvancarova M; Holth A; Katz B; Risberg B; Kristensen G; Lindemann K
BMC Cancer; 2016 Aug; 16():596. PubMed ID: 27488577
[TBL] [Abstract][Full Text] [Related]
6. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.
Kommoss S; Hartkopf AD; Krämer B; Bunz AK; Grevenkamp F; Kommoss F; Pasternak J; Arbabi SM; Wallwiener M; Staebler A; Lax SF; Brucker SY; Taran FA
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2183-2188. PubMed ID: 28710714
[TBL] [Abstract][Full Text] [Related]
7. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
Bosse T; Nout RA; Stelloo E; Dreef E; Nijman HW; Jürgenliemk-Schulz IM; Jobsen JJ; Creutzberg CL; Smit VT
Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
[TBL] [Abstract][Full Text] [Related]
8. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
[TBL] [Abstract][Full Text] [Related]
9. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
11. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
Soovares P; Pasanen A; Bützow R; Lassus H
Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma.
Kihara A; Yoshida H; Watanabe R; Takahashi K; Kato T; Ino Y; Kitagawa M; Hiraoka N
Am J Surg Pathol; 2017 Jul; 41(7):896-905. PubMed ID: 28418994
[TBL] [Abstract][Full Text] [Related]
13. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.
Zeimet AG; Reimer D; Huszar M; Winterhoff B; Puistola U; Azim SA; Müller-Holzner E; Ben-Arie A; van Kempen LC; Petru E; Jahn S; Geels YP; Massuger LF; Amant F; Polterauer S; Lappi-Blanco E; Bulten J; Meuter A; Tanouye S; Oppelt P; Stroh-Weigert M; Reinthaller A; Mariani A; Hackl W; Netzer M; Schirmer U; Vergote I; Altevogt P; Marth C; Fogel M
J Natl Cancer Inst; 2013 Aug; 105(15):1142-50. PubMed ID: 23781004
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker.
Pasanen A; Loukovaara M; Tuomi T; Bützow R
Int J Gynecol Cancer; 2017 Sep; 27(7):1318-1324. PubMed ID: 29059097
[TBL] [Abstract][Full Text] [Related]
15. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
16. L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.
Klat J; Mladenka A; Dvorackova J; Bajsova S; Simetka O
Anticancer Res; 2019 Jan; 39(1):421-424. PubMed ID: 30591489
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of β-Catenin and L1CAM Expressions in Type I Endometrial Carcinoma.
Manule Y; Miskad UA; Masadah R; Nelwan B; Cangara MH; Mardiati M
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1413-1417. PubMed ID: 37116166
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of peritoneal cytology in low-intermediate risk endometrial cancer.
Scott SA; van der Zanden C; Cai E; McGahan CE; Kwon JS
Gynecol Oncol; 2017 May; 145(2):262-268. PubMed ID: 28359690
[TBL] [Abstract][Full Text] [Related]
19. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
20. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
Kommoss FK; Karnezis AN; Kommoss F; Talhouk A; Taran FA; Staebler A; Gilks CB; Huntsman DG; Krämer B; Brucker SY; McAlpine JN; Kommoss S
Br J Cancer; 2018 Aug; 119(4):480-486. PubMed ID: 30050154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
